
Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 28
Selected: 0
NCT ID | Title | ||
---|---|---|---|
NCT03368729 | Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer | ||
NCT01982448 | Cisplatin vs Paclitaxel for Triple Negative Breast Cancer | ||
NCT04443348 | Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) | ||
NCT04841148 | Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer | ||
NCT05721248 | STOP-HER2: Stopping Trastuzumab in HER2+ MBC | ||
NCT06533826 | TReatment of ADC-Refractory Breast CancEr with Dato-DXd or T-DXd: TRADE DXd | ||
NCT02384239 | A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer | ||
NCT01494662 | HKI-272 for HER2-Positive Breast Cancer and Brain Metastases | ||
NCT05501704 | ETHAN - ET for Male BC | ||
NCT02743910 | Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer | ||
NCT00999804 | Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy | ||
NCT02457910 | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer | ||
NCT06551116 | QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer | ||
NCT04584255 | Niraparib + Dostarlimab in BRCA Mutated Breast Cancer | ||
NCT06774027 | Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer | ||
NCT04425018 | MARGetuximab Or Trastuzumab (MARGOT) | ||
NCT00146536 | Upstaging of ALH/LCIS Found on Core Biopsy Based on Subsequent Excisional Biopsy | ||
NCT00577122 | Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer | ||
NCT01101425 | Male Breast Cancer: Understanding the Biology for Improved Patient Care | ||
NCT01937117 | Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer | ||
NCT00977119 | Investigation of Genetic Determinants of Capecitabine Toxicity | ||
NCT03501979 | Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD | ||
NCT00925652 | Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer | ||
NCT03095352 | Pembrolizumab with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease | ||
NCT03971409 | Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | ||
NCT02928978 | Ruxolitinib for Premalignant Breast Disease | ||
NCT06439693 | The SAPPHO Study: A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | ||
NCT03400254 | Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER") |